

\$9.5M PLACEMENT AND \$2M SPP TO ACCELERATE DEVELOPMENT OF INOVIQ'S OVARIAN CANCER TEST AND THERAPEUTIC PROGRAM

- A\$9.5 million placement completed to institutional and sophisticated investors at \$0.35 per Share
- Tian An Medicare Limited committed A\$5m as cornerstone investor to support growth and commercialisation initiatives
- Share purchase plan (SPP) to be offered to eligible shareholders, targeting A\$2 million plus oversubscriptions at the Company's discretion
- Proceeds will be used to accelerate clinical validation and LDT commercialisation of the EXO-OC™ ovarian cancer test and preclinical development of the exosome therapeutic program for solid tumours
- PAC Partners Securities Pty Ltd was the Lead Manager and Underwriter, supported by Arlington Group Asset Management Limited
- Proforma net cash balance will be approximately \$17.2m following placement and SPP completion¹, less raise costs (inclusive of 5% fees on the placement)

INOVIQ Limited (ASX: IIQ) (INOVIQ or the **Company**) is pleased to announce a placement to institutional and sophisticated investors, to raise \$9.5 million (before costs). This is a placement of 27,142,860 fully paid ordinary shares (**Shares**) at \$0.35 per Share (**Placement**), a 15.7% discount to the last traded price.

The Placement was supported, with **Tian An Medicare Limited**, a Hong Kong-listed investment holding company (HKG:0383), committing A\$5m as cornerstone investor. Tian An Medicare has investments across hospital, healthcare and eldercare, and is positioning to be a significant player in healthcare and eldercare in China.

Tian An Medicare requested that Mr Peter Gunzburg, a former Chairman of INOVIQ and a Top 20 shareholder, rejoin the Board as a non-executive director. Mr Gunzburg will be appointed at completion of the placement and be nominated for formal election at IIQ's AGM on 27 November 2025. Mr Gunzburg participated in the Placement for \$100,000.

Tian An Medicare Executive Director Kong Muk Yin said: "Tian An Medicare's investment in INOVIQ reflects our belief in the transformative potential of its EXO-OC™ ovarian cancer test to improve women's health outcomes through earlier detection and intervention. Our Group's extensive network across hospitals, clinical laboratories, eldercare and healthcare businesses in China enables us to support the commercialisation of EXO-OC in China. We see a compelling medical, societal and ethical imperative to accelerate access to this important screening tool."

INOVIQ CEO Dr Leearne Hinch said: "We are delighted to welcome Tian An Medicare as a cornerstone investor in INOVIQ. Their expertise and strategic relationships in China will be beneficial in advancing the commercialisation of our ovarian cancer test. With 100% sensitivity for early-stage ovarian cancer and over 99.6% specificity in studies to date, EXO-OC represents a potential major advancement in cancer diagnostics. This capital raising funds the EXO-OC™ test to LDT readiness and accelerates our

¹ Based on audited 30 June 2025 cash balance as disclosed in the 30 June 2025 Annual Report, Placement proceeds, costs of the capital raising and assuming \$2m proceeds under the SPP.

therapeutic development program, enabling the achievement of key value-creating milestones for shareholders."

INOVIQ Chairman David William said: *"We welcome Tian An Medicare and other sophisticated investors to the share register. We also welcome Mr Peter Gunzburg back to the INOVIQ Board. Peter's history and understanding of INOVIQ's technology and strategic direction will be valuable as we enter this next phase of growth."*

1. Capital Raising Overview

INOVIQ is pleased to announce a capital raising comprising a:

- placement to raise A\$9.5 million from the issue of Shares to institutional and sophisticated investors (**Placement**); and
- share purchase plan to existing and eligible shareholders to raise A\$2.0 million (**SPP**) with the capacity to accept oversubscriptions at the Company's discretion, (collectively, the **Offer** or **Capital Raising**).

The offer price for the Shares under the Placement and SPP will be A\$0.35 per Share (**Offer Price**), representing a discount of:

- 15.7% to the last closing price on Wednesday, 8 October 2025 of A\$0.415 per Share; and
- 15.3% to the 5-day volume-weighted average price of A\$0.413 per Share.

Each Share issued under the Capital Raising will rank equally with existing Shares from the date of issue.

2. Capital Raising Details

Placement

The Placement raised A\$9.5 million through the issue of 27,142,860 Shares. \$3m of the Placement was underwritten by PAC Partners Securities Pty Ltd (**PAC Partners**), with the support of Arlington Group Asset Management Limited as advisor.

The Placement will be made without a prospectus in reliance on section 708A(5) of the *Corporations Act 2011* (Cth) (**Act**). Settlement of the Placement is expected to occur on Thursday, 16 October 2025.

The Shares will be issued under the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A.

For personal use only

SPP

Following completion of the Placement, INOVIQ will offer new Shares under a SPP to existing and eligible shareholders with a registered address in Australia or New Zealand as at 7.00pm (Sydney time) on Friday, 10 October 2025 (**Eligible Shareholders**) to apply for up to \$30,000 of Shares free of any brokerage, commission or transaction costs.

The Company is seeking to raise a further \$2 million through the SPP, with the capacity to accept oversubscriptions at the Company's discretion, at \$0.35 per share. INOVIQ reserves the right to scale back oversubscriptions under the SPP in its absolute discretion. In the event of a scale back occurring, Eligible Shareholders may not receive the full number of Shares applied for under the SPP and the difference in any application monies will be refunded (without interest) following the issue of Shares under the SPP.

Full details of the SPP will be set out in the SPP offer booklet which is expected to be released to the ASX and dispatched to Eligible Shareholders on or about Friday, 17 October 2025. The SPP is scheduled to open on Friday, 17 October 2025 and close on Wednesday, 29 October 2025.

3. Use of Funds

The funds raised in the Capital Raising will be used to accelerate clinical validation and LDT commercialisation of the EXO-OC Ovarian Cancer screening test and expedite *in-vivo* preclinical studies for its exosome therapeutic program for solid tumours.

Purpose	\$ million
Sales, marketing and business development	0.7
Research and Development (Exosome diagnostics, Exosome therapeutics and SubB2M)	9.0
Administrative and corporate costs	1.0
Offer costs	0.8
Total funds raised	11.5²

² Indicative only. Assumes \$11.5m is raised . If SPP subscriptions are more/less than \$2m, then the use of funds in the table above will be adjusted pro rata.

4. Indicative timetable

The timetable below is indicative only and subject to change. The Company reserves the right to alter the dates below in its discretion without prior notice, subject to the ASX Listing Rules and the Act. The commencement of trading of new Shares is subject to confirmation from ASX.

Event	Date
Trading halt	Thursday, 9 October 2025
Record date for SPP	7pm (Sydney time) on Friday, 10 October 2025
Announcement of completion of Placement and recommencement of trading	Monday, 13 October 2025
Settlement of new Shares issued under the Placement	Thursday, 16 October 2025
Allotment and normal trading of new Shares under the Placement	Friday, 17 October 2025
SPP offer opening date	Friday, 17 October 2025
SPP offer closing date (5:00pm, Sydney time)	Wednesday, 29 October 2025
Announcement of results of SPP	Monday, 3 November 2025
Settlement of new Shares under the SPP	Tuesday, 4 November 2025
Allotment of new Shares under the SPP	Wednesday, 5 November 2025

5. Further Information

If you have any questions in relation to the Capital Raising, please contact the Offer Information Line on 1300 850 505 (within Australia) or +61 3 9415 5000 (outside of Australia) between 8.30am and 5.00pm Monday to Friday. Please consult with your broker, solicitor, accountant, financial adviser or other professional advisers if you have any questions in relation to this announcement.

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leeorne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.